{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,11]],"date-time":"2026-03-11T06:38:14Z","timestamp":1773211094183,"version":"3.50.1"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T00:00:00Z","timestamp":1455148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-sa\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Br J Cancer"],"published-print":{"date-parts":[[2016,3]]},"DOI":"10.1038\/bjc.2015.440","type":"journal-article","created":{"date-parts":[[2016,2,11]],"date-time":"2016-02-11T23:25:02Z","timestamp":1455233102000},"page":"505-509","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial"],"prefix":"10.1038","volume":"114","author":[{"name":"on behalf of the Australasian Gastro-Intestinal Trials Group (AGITG)","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Niall C","family":"Tebbutt","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timothy J","family":"Price","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Danielle A","family":"Ferraro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicole","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anne-Sophie","family":"Veillard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Merryn","family":"Hall","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin M","family":"Sjoquist","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nick","family":"Pavlakis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Strickland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suresh C","family":"Varma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Prasad","family":"Cooray","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosemary","family":"Young","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Craig","family":"Underhill","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer A","family":"Shannon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vinod","family":"Ganju","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Val","family":"Gebski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2016,2,11]]},"reference":[{"issue":"9","key":"BFbjc2015440_CR1","doi-asserted-by":"publisher","first-page":"1435","DOI":"10.1200\/JCO.2007.13.9378","volume":"26","author":"S-E Al-Batran","year":"2008","unstructured":"Al-Batran S-E, Hartmann JT, Probst S, Schmalenberg H, Hollerbach S, Hofheinz R, Rethwisch V, Seipelt G, Homann N, Wilhelm G, Schuch G, Stoehlmacher J, Derigs HG, Hegewisch-Becker S, Grossmann J, Pauligk C, Atmaca A, Bokemeyer C, Knuth A, J\u00e4ger E Arbeitsgemeinschaft Internistische Onkologie (2008) Phase III trial in metastatic gastroesophageal adenocarcinoma with fluorouracil, leucovorin plus either oxaliplatin or cisplatin: a study of the Arbeitsgemeinschaft Internisticsche Onkologie. J Clin Oncol 26 (9): 1435\u20131442.","journal-title":"J Clin Oncol"},{"issue":"15\u2013suppl","key":"BFbjc2015440_CR2","doi-asserted-by":"crossref","first-page":"abstract 4023","DOI":"10.1200\/jco.2013.31.15_suppl.4023","volume":"31","author":"N Cook","year":"2013","unstructured":"Cook N, Marshall A, Blazeby J, Bridgewater J, Wadsley J, Coxon F, Mansoor W, Madhusudan S, Falk S, Middleton G, Swinson D, Chau I, Thompson J, Cunningham D, Kareclas P, Dunn J, Ford H (2013) Cougar-01: a randomised phase III study of docetaxel versus active symptom control in patients with relapsed esophago-gastric adenocarcinoma. J Clin Oncol 31 (15\u2013suppl): abstract 4023.","journal-title":"J Clin Oncol"},{"key":"BFbjc2015440_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1056\/NEJMoa073149","volume":"358","author":"D Cunningham","year":"2008","unstructured":"Cunningham D, Starling N, Rao S, Iveson T, Nicolson M, Coxon F, Middleton G, Daniel F, Oates J, Norman AR Upper Gastrointestinal Clinical Studies Group of the National Cancer Research Institute of the United Kingdom (2008) Capecitabine and oxaliplatin for advanced esophagogastric cancer. N Engl J Med 358: 36\u201346.","journal-title":"N Engl J Med"},{"key":"BFbjc2015440_CR4","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1023\/A:1008243606668","volume":"8","author":"B Glimelius","year":"1997","unstructured":"Glimelius B, Ekstrom K, Hoffman K, Graf W, Sj\u00f6d\u00e9n PO, Haglund U, Svensson C, Enander LK, Linn\u00e9 T, Sellstr\u00f6m H, Heuman R (1997) Randomized comparison between chemotherapy plus best supportive care with best supportive care in advanced gastric cancer. Ann Oncol 8: 163\u2013168.","journal-title":"Ann Oncol"},{"issue":"20","key":"BFbjc2015440_CR5","doi-asserted-by":"publisher","first-page":"2040","DOI":"10.1056\/NEJMoa071834","volume":"357","author":"DJ Jonker","year":"2007","unstructured":"Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, Tebbutt NC, van Hazel G, Wierzbicki R, Langer C, Moore MJ (2007) Cetuximab for the treatment of colorectal cancer. N Engl J Med 357 (20): 2040\u20132048.","journal-title":"N Engl J Med"},{"key":"BFbjc2015440_CR6","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1136\/jcp.2005.034298","volume":"59","author":"R Langer","year":"2006","unstructured":"Langer R, Von Rahden BH, Nahrig J, Von Weyhern C, Reiter R, Feith M, Stein HJ, Siewert JR, H\u00f6fler H, Sarbia M (2006) Prognostic significance of expression patterns of c-erbB-2, p53, p16INK4A, p27KIP1, cyclin D1 and epidermal growth factor receptor in esophageal adenocarcinoma: a tissue microarray study. J Clin Pathol 59: 631\u2013634.","journal-title":"J Clin Pathol"},{"issue":"6","key":"BFbjc2015440_CR7","first-page":"1517","volume":"25","author":"J Lee","year":"2011","unstructured":"Lee J, Seo JW, Jun HJ, Ki CS, Park SH, Park YS, Lim HY, Choi MG, Bae JM, Sohn TS, Noh JH, Kim S, Jang HL, Kim JY, Kim KM, Kang WK, Park JO (2011) Impact of MET amplification on gastric cancer: possible roles as a novel prognostic marker and a potential therapeutic target. Oncol Rep 25 (6): 1517\u20131524.","journal-title":"Oncol Rep"},{"issue":"1","key":"BFbjc2015440_CR8","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1245\/s10434-007-9596-0","volume":"15","author":"E Lieto","year":"2008","unstructured":"Lieto E, Ferraraccio F, Orditura M, Castellano P, Mura AL, Pinto M, Zamboli A, De Vita F, Galizia G (2008) Expression of vascular endothelial growth factor (VEGF) and epidermal growth factor receptor (EGFR) is an independent prognostic indicator of worse outcome in gastric cancer patients. Ann Surg Oncol 15 (1): 69\u201379.","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"BFbjc2015440_CR9","doi-asserted-by":"publisher","first-page":"490","DOI":"10.1016\/S1470-2045(13)70102-5","volume":"14","author":"F Lordick","year":"2013","unstructured":"Lordick F, Kang Y-K, Chung H-C, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, G\u00f6tte H, Melez\u00ednkov\u00e1 H, Moehler M Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators (2013) Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol 14 (6): 490\u2013499.","journal-title":"Lancet Oncol"},{"issue":"1","key":"BFbjc2015440_CR10","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/1097-0142(19930701)72:1<37::AID-CNCR2820720109>3.0.CO;2-P","volume":"72","author":"AM Murad","year":"1993","unstructured":"Murad AM, Santiago FF, Petroianu A, Rocha PR, Rodrigues MA, Rausch M (1993) Modified therapy with 5-fluorouracil, doxorubicin, and methotrexate in advanced gastric cancer. Cancer 72 (1): 37\u201341.","journal-title":"Cancer"},{"issue":"6","key":"BFbjc2015440_CR11","first-page":"955","volume":"16","author":"K Muro","year":"2004","unstructured":"Muro K, Hamaguchi T, Ohtsu A (2004) A phase II study of single-agent docetaxel in patients with metastatic esophageal cancer. Ann Oncol 2004 16 (6): 955\u2013959.","journal-title":"Ann Oncol 2004"},{"key":"BFbjc2015440_CR12","doi-asserted-by":"publisher","first-page":"941954","DOI":"10.1155\/2012\/941954","volume":"2012","author":"D Navarini","year":"2012","unstructured":"Navarini D, Gurski RR, Madalosso CA, Aita L, Meurer L, Fornari F (2012) Epidermal growth factor receptor in esophageal adenocarcinoma: relationship with tumor stage and survival after esophagectomy. Gastroenterol Res Pract 2012: 941954.","journal-title":"Gastroenterol Res Pract"},{"issue":"3","key":"BFbjc2015440_CR13","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1038\/sj.bjc.6605522","volume":"102","author":"NC Tebbutt","year":"2010","unstructured":"Tebbutt NC, Cummins MM, Sourjina T, Strickland A, Van Hazel G, Ganju V, Gibbs D, Stockler M, Gebski V, Zalcberg J Australasian Gastro-Intestinal Trials Group (2010) Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. Br J Cancer 102 (3): 475\u2013481.","journal-title":"Br J Cancer"},{"key":"BFbjc2015440_CR14","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1038\/bjc.2013.41","volume":"108","author":"NC Tebbutt","year":"2013","unstructured":"Tebbutt NC, Parry MM, Zannino D, Strickland AH, Van Hazel GA, Pavlakis N, Ganju V, Mellor D, Dobrovic A, Gebski VJ Australasian Gastro-Intestinal Trials Group (AGITG (2013) Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. Br J Cancer 108: 771.","journal-title":"Br J Cancer"},{"issue":"31","key":"BFbjc2015440_CR15","doi-asserted-by":"publisher","first-page":"4991","DOI":"10.1200\/JCO.2006.06.8429","volume":"24","author":"E Van Cutsem","year":"2006","unstructured":"Van Cutsem E, Moiseyenko VM, Tjulandin S, Majlis A, Constenla M, Boni C, Rodrigues A, Fodor M, Chao Y, Voznyi E, Risse ML, Ajani JA V325 Study Group (2006) Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: a report of the V325 Study Group. J Clin Oncol 24 (31): 4991\u20134997.","journal-title":"J Clin Oncol"},{"issue":"13","key":"BFbjc2015440_CR16","doi-asserted-by":"publisher","first-page":"1658","DOI":"10.1200\/JCO.2006.08.1620","volume":"25","author":"E Van Cutsem","year":"2007","unstructured":"Van Cutsem E, Peeters M, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, Amado RG (2007) Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25 (13): 1658\u20131664.","journal-title":"J Clin Oncol"},{"key":"BFbjc2015440_CR17","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1016\/S1470-2045(13)70096-2","volume":"14","author":"T Waddell","year":"2013","unstructured":"Waddell T, Chau I, Cunningham D, Gonzalez D, Okines AF, Okines C, Wotherspoon A, Saffery C, Middleton G, Wadsley J, Ferry D, Mansoor W, Crosby T, Coxon F, Smith D, Waters J, Iveson T, Falk S, Slater S, Peckitt C, Barbachano Y (2013) Epirubicin, oxaliplatin, and capecitabine with or without panitumumab for patients with previously untreated advanced oesophagogastric cancer (REAL3): a randomised, open-label phase 3 trial. Lancet Oncol 14: 481\u2013489.","journal-title":"Lancet Oncol"},{"issue":"18","key":"BFbjc2015440_CR18","doi-asserted-by":"publisher","first-page":"2903","DOI":"10.1200\/JCO.2005.05.0245","volume":"24","author":"AD Wagner","year":"2006","unstructured":"Wagner AD, Grothe W, Haerting J, Kleber G, Grothey A, Fleig WE (2006) Chemotherapy in advanced gastric cancer: a systematic review and meta-analysis based on aggregate data. J Clin Oncol 24 (18): 2903\u20132909.","journal-title":"J Clin Oncol"}],"container-title":["British Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/bjc2015440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015440","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/bjc2015440.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,18]],"date-time":"2023-05-18T09:31:18Z","timestamp":1684402278000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/bjc2015440"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,11]]},"references-count":18,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["BFbjc2015440"],"URL":"https:\/\/doi.org\/10.1038\/bjc.2015.440","relation":{},"ISSN":["0007-0920","1532-1827"],"issn-type":[{"value":"0007-0920","type":"print"},{"value":"1532-1827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,11]]},"assertion":[{"value":"26 February 2015","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2015","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2015","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 February 2016","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Niall Tebbutt, Timothy Price and Jennifer Shannon have had consultant or advisory roles for Amgen. Niall Tebbutt has given expert testimony for and has had research funding from Amgen. All other authors have no relevant relationships to disclose.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}